ethicsThursday, July 16
Today's ethics coverage spans three distinct threads: a sitting president's potential insider trading, a startup's dystopian organ-growing scheme, and the deaf community's exclusion from gene-editing debates. Each raises uncomfortable questions about power, consent, and who gets to decide what's ethical.
The biggest story today is the CNN investigation into Trump's stock promotions on Truth Social, which raises clear ethical and legal red flags.
CNN found Trump promoted over 20 companies on Truth Social within days of buying their stock, including Nvidia. The ethical question is whether a president can use his platform to move markets for personal gain.
A White House staffer is under investigation for betting on prediction markets tied to Trump's remarks. It's a smaller story but reinforces the day's theme of insider advantage.
Two very different bioethics stories: a startup trying to grow organs in brainless humanoids, and the deaf community pushing back against gene-editing assumptions.
R3 Bio, a secretive startup, is developing brain-free humanoid 'organ sacks' for harvesting. The company tried to suppress an interview about it, which only makes the ethical questions louder.
The Guardian editorial argues that as CRISPR advances, we must acknowledge darker uses like eugenics, not just medical ones. It's a reminder that the public conversation is still catching up.
The British Deaf Association says deaf people have been excluded from gene-editing debates, and polling doesn't support using it for non-life-threatening conditions. A direct challenge to the 'inevitability' narrative.
Trump promoted companies on Truth Social days after buying their stockswww.cnn.com
space exploration roundup
medical research roundup
geopolitics roundup
inspiration roundup
economics roundup
comics roundup
